word count: 271 Manuscript word count: 4116 ACCEPTED MANUSCRIPT ABSTRACT Excessive daytime sleepiness (EDS) is one of the earliest and most common non-motor symptoms of PD, substantially impacting on patient's quality of life. Using the Parkinson's Progression Markers Initiative database, we performed a case-control study to investigate whether dopaminergic deficit is associated with the development of EDS using dopaminergic specific single photon emission computed tomography (SPECT) molecular imaging of dopamine transporters (DAT). We enrolled 84 early de novo PD patients with EDS and 84 without EDS, who were matched for age, gender, age of diagnosis, years of education and disease duration. We assessed and compared semi-quantified [ 123 I]FP-CIT SPECT, and motor and non-motor features amongst these two groups, alongside exploring the clinical and imaging correlates of EDS and the predictive significance of these markers in the development of EDS. PD patients with EDS had worse non-motor (MDS-UPDRS Part-I, P<0.001) and motor (MDS-UPRDS Part-II, P=0.005) experiences of daily living, as well as worse autonomic (SCOPA-AUT, P<0.0001) and cognitive (MoCA P=0.05) function, depression (GDS, P=0.002), and reduced caudate DAT ([ 123 I]FP-CIT, P=0.024) compared to PD patients without EDS. Lower caudate [ 123 I]FP-CIT values correlated with higher EDS scores (r=-0.192, P=0.013). Among patients without EDS, 47 PD patients (56%) developed EDS over a median follow-up of 36 months. Cox multivariate analysis including all clinical and imaging data available, revealed that abnormal caudate [ 123 I]FP-CIT uptake (P=0.030)
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INTRODUCTION
Excessive daytime sleepiness (EDS) is one of the most common and troublesome non-motor symptoms (NMS) in both early and advanced Parkinson's disease (PD) [1] . Although a range of NMS are primarily reported to be associated with non-dopaminergic deficits, such as depression [2] , BMI changes [3] and fatigue [4] , the dopaminergic system has also been identified as a pivotal contributor to non-motor symptoms in PD [5] , reflecting the multisystem nature of the disorder. Politis and colleagues reported in vivo evidence of dopamine dysfunction in the hypothalamus of PD patients, suggesting a dopaminergic contribution to several non-motor symptoms, including sleep disorders, neuro-endocrinal problems and autonomic dysfunction [6] . NMS are often poorly identified and inadequately treated, highlighting the challenge attached with NMS management. Therefore, gaining an insight into the neurobiological mechanisms underlying these symptoms could improve management and the development of novel treatments.
The clinical heterogeneity of PD has led to the discovery of phenotypic subtypes of motor and non-motor symptoms [7] . Patients with daytime sleepiness, along with cognitive impairment, autonomic dysfunction and depression were recognised as a specific subtype of PD [7] , instigating an interest in the clinical associations of EDS, alongside phenotypic and neurobiological risk factors of EDS development.
An amalgamation of dopaminergic denervation, nocturnal sleep disruption and dopaminergic medication is likely to be causative [8, 9] , though several studies have suggested that EDS may be a primary feature of PD, unrelated to dopaminergic therapies or nocturnal sleep disturbances [10] . A magnetic resonance imaging (MRI) brain morphometry revealed that EDS in PD patients was related to atrophy of the medial cerebellar peduncle, suggesting that degeneration of the pontomedullary respiratory centres may underlie EDS development in PD [11] . Further, patients experiencing daytime sleepiness demonstrated a prominent impairment in circadian melatonin secretion, suggesting that circadian dysfunction may underlie excessive sleepiness [12] . A genetic component contributing to the pathogenesis of EDS has also been reported [13] . Furthermore, Saper and colleagues proposed that a 'flip-flop switch'
is responsible for the sleep-wake cycle in primates, whereby the suprachiasmatic nucleus regulates the internal rhythm between two switches, with hypocretin potentially playing a regulatory role [14] . The quantity of hypocretin-producing neurons and the CSF level of hypocretin-1 have been shown to be reduced in PD [15] [16] [17] , with consistent loss of
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hypocretin-producing neurons demonstrated by a reduction in the number of post-mortem hypothalamic hypocretin neurons, acknowledged as the 'gold standard' [16, 17] .
Disease variables found to be associated with EDS include longer disease duration, older age, severity of motor manifestations, depression, cognitive impairment and, non-tremor dominant motor phenotype [8, 18] , though not all epidemiological studies of PD have discovered the same picture or disease variables to be associated with EDS [19] .
Studies investigating EDS and dopaminergic pathways discovered that subjective daytime sleepiness is associated with striatonigral degeneration [20] , though others have proposed that it may be associated with extrastriatal dopaminergic loss in specific brain structures involved in alertness [21] . Thus, the role of the striatum in the development of EDS remains unclear.
We aimed to explore the relationship between EDS and striatal dopamine terminals, using patients. We hypothesised that EDS would be associated with striatal dopaminergic denervation.
METHODS
The Parkinson's Progression Markers Initiative (PPMI) is a five-year observational, international, multi-centre study designed to provide insight into disease aetiology by identifying PD progression biomarkers. The present study was written according to the STROBE guidelines. This study is registered with ClinicalTrials.gov, number NCT01141023.
Cohort selection
We included PD patients aged >30 years old, who had a disease duration ≤ 2 years and were not on dopamine replacement therapy. Institutional review boards approved the study and written informed consent was obtained from all participants. From a total of 412 patients with PD, 84 had EDS according to the Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part-I, item 1.8 'daytime sleepiness'. This self-reported, self-completed instrument consists of 5 statements, rating from 0: normal to 4: severe, with a higher rating corresponding to a higher degree of EDS. The presence of EDS was defined as daytime
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sleepiness interfering with daily activities and social interactions (cut-off >1). All clinical and imaging assessments were performed in subjects who were not receiving any dopaminergic medication, at baseline. The cut-off values considered abnormal for all clinical and imaging variables were calculated as 2 S.D. from the mean of HCs, as previously stated [22] . 
Dopaminergic therapy
Study participants could start dopamine replacement therapy (DRT) at any point after baseline as part of routine clinical care. A participant was considered to have received DRT (dopamine agonists, levodopa, monoamine oxidase type B (MAO-B) inhibitors) from the first time it was recorded at an annual study visit. Information about medication dosages was not readily ascertained in the database and is not included.
Statistical methods
Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS), achieving P<0.10 on univariate analysis. Only the time to occurrence of the first event in a category for a given subject was used. To increase the stability of our findings, we confirm that the outcome present at one visit was still present at subsequent visits. Statistical significance was set at P<0.05, Bonferroni corrected. 
RESULTS
Dopaminergic imaging
Structural imaging
There were no differences in cortical thickness or subcortical volumes between PD patients with EDS compared to those without (P>0.1). Figure 2A ). No differences were found in motor symptom severity between PD with and without EDS (MDS-UPRDS Part-III, P>0.10).
Clinical phenotype analysis
Correlations
Higher EDS scores at baseline were associated with decreased caudate [ 123 I]FP-CIT binding 
EDS predictive analysis
Of the 84 PD patients without EDS at baseline, 34 Although the correlations between EDS and cognitive impairment, autonomic dysfunction and depression were somewhat weak, likely due to the sample size of the cohort, they were found to be associated, particularly when comparing the PD-EDS and PD non-EDS cohorts. This is consistent with previous studies which have revealed patterns of coherency amidst motor and non-motor domains within PD. van Rooden et al. [24] discovered that daytime sleepiness was often present with depression, cognitive impairment, autonomic dysfunction and psychotic and axial symptoms, with a second pattern characterised by sleep disturbances, depression and cognitive impairment, highlighting a conspicuous disease profile implicated with sleep. EDS has also been found to be an independent predictive factor for cognitive difficulties in the general elderly population [25] , suggesting EDS is a significant risk factor for cognitive deficits. Intriguingly, the caudate dopaminergic function has been recognised as a fundamental node in supporting cognitive domains. Previous findings have illustrated that loss of dopaminergic projections to the caudate correlate with degree of dementia in PD [26] , alongside others reporting that a reduction in caudate uptake of [ 18 F]DOPA is associated with verbal and visual memory functioning, verbal fluency and, delayed recall [27] highlighting that the functional integrity of presynaptic dopaminergic synthesis is crucial for cognitive function in PD. More recently, in a PPMI study, Schrag and colleagues demonstrated that dopaminergic denervation within the caudate, alongside four other variables, predicted cognitive impairment at 2 years [28] . This is particularly interesting given that Schrag explored a larger version of, essentially, the same cohort and reported similar findings.
Therefore, the mechanisms underlying the development of EDS and cognitive problems may share an overlapping dopaminergic substrate. Therefore, the mechanisms underlying the development of EDS and cognitive problems may share an overlapping dopaminergic substrate.
Dopamine has been reported to promote wakefulness in a range of animal models including cats and drosophila [29, 30] , though studies have also demonstrated its association with sleepiness and the sleep state [31] . This discrepancy can be explained by dopamine mediating both wakefulness and sleepiness depending on its concentration. Studies have, for example,
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demonstrated that either excessive or insufficient dopamine impairs cognitive functions [32] , suggesting that a similar mechanism may underlie the varying sleep disorders in PD, particularly because discrete classes of receptors may be activated by varying concentrations of dopamine based on receptor affinity [9] .
The caudate nucleus is a major receptive component of the basal ganglia, embedded within its large neural network. The striatum is the focal output structure, receiving afferent fibres from distinct cortical areas, projecting them on to the thalamus and brainstem for auxiliary propagation via pallidum back to cortex [33] . Distinct functional zones have been proposed, within the caudate, based on their innervation by specific cortical areas [33] . It is not surprising that the caudate has surfaced as a common node in the regulatory systems involved in sleep problems, arousal and executive function, due to its complex role in regulating the impact of impulses between the thalamus and cortex. Hyper-arousal indices have emerged in studies that have specifically disrupted caudate function, highlighting that caudate lesions might induce hyper-responsivity and behavioural restlessness [30] .
Recent studies have implicated the basal ganglia and its respective structures in arousal and the sleep-wake cycle. Neurotoxic lesion studies have demonstrated the pivotal role of the basal ganglia in regulating the sleep-wake cycle. Specifically, bilateral striatal lesions result in reduced wakefulness, which is attenuated when the striatal (caudoputamen) lesions include the nucleus accumbens [34] . These findings highlight that the caudate is involved in promoting wakefulness whereas the nucleus accumbens primarily enhances sleepiness. In this direction, our results highlight that a loss of DAT, therefore dopamine, within the caudate, could in fact cause sleepiness in PD patients. However, it is also important to recognise the role of other major nuclei including the globus pallidus, thalamus and substantia nigra. Cell body-specific lesioning of the globus pallidus externa has resulted in insomnia, with rats demonstrating a prominent increase of up to 45% [34] . Further, neuronal loss within the substantia nigra, excluding the globus pallidus, consequently affected sleep-wake behaviour, specifically presenting as an increase of wakefulness [34, 35] . Lazarus and colleagues propose that the nucleus accumbens, in particular, is a key node in the circuitry for sleep [36] .
A 2A receptors residing in the nucleus accumbens are fundamental for the wakefulness induced by caffeine, and presumably modulate neural substrates through which arousal is also produced by dopamine. The nucleus accumbens encompasses GABAergic projections to an array of targets, including the ventral tegmental area (VTA), ventral pallidum,
parabrachial nucleus and lateral hypothalamus, which are recognised to contribute to arousal [36] .
The dopaminergic system has been acknowledged to play key role in promoting wakefulness as demonstrated by several studies. Eban-Rothschild and colleagues revealed the role of VTA dopaminergic neurons in maintaining the awake state, by recording calcium activity in mice [37] . They found that optogenetic stimulation of VTA dopaminergic neurons initiated and Studies have also demonstrated that modafinil, which is commonly used to treat daytime sleepiness in PD, works by enhancing extracellular levels of dopamine within the nucleus accumbens and medial prefrontal cortex [40] The arousal-inducing effects of modafinil is abolished in mice following DAT knockout [41] thus implicating the loss of DAT in the pathophysiology of daytime sleepiness, potentially through a loss of dopamine clearance from the synapses. Qu and colleagues demonstrated that the arousal effects of modafinil is exclusively mediated via both D 1 and D 2 receptors, with D 2 receptors being of particular significance [42] .
It is also important to consider that a dopamine caudate denervation could covariate with non- activity throughout the brain. Hypothalamic changes, in particular, have been associated with dopaminergic pathology by using PET imaging [43] , which has greater resolution for small areas. These changes are likely to play a key role the development of EDS, given the established role of hypothalamic neuropeptides, hypocretins (orexins), in regulating sleep and arousal states [16, 17, 44] . Further, we found that higher EDS scores were associated with higher global non-motor symptoms burden, worse motor experiences of daily living, autonomic dysfunction, cognitive impairment and depression. The lower caudate uptake in our cohort of PD patients with EDS could, therefore, be reflecting a more severe disease that has already spread to the caudate nuclei, which in turn could be associated with the increased severity of non-motor symptoms, including EDS. In this direction, EDS may have no direct link with dopaminergic denervation, but is early associated with altered [ 123 I]FP-CIT binding in the caudate. Further, despite the efforts that were undertaken in standardising [ 123 I]FP-CIT scans among the different PPMI centres, the method per se is interference-prone, especially in a multi-centre approach. We also did not take into consideration important confounding factors such as comorbidities and non-dopaminergic medication, as well as the fact that PD patients with EDS exhibited a more severe disease from several perspectives. Therefore, the pathophysiological causality of caudate denervation to EDS is disputable.
It is important to note, however, that we explored the potential covariating nature of reduced caudate [ 123 I]FP-CIT by investigating extrastriatal morphological changes. As well as finding no structural differences between PD patients with EDS compared to those without, cortical and subcortical alterations did not predict the manifestation of EDS, even at the univariate level. This highlights that extrastriatal degeneration may not be a causal factor underlying EDS within early-stage PD patients. Further, our results indicate that the loss of DAT within the caudate does not reflect the loss of neurons, therefore suggesting that early functional and/or molecular changes in PD may be contributing to the pathology of EDS. We were, however, unable to explore the structural integrity of the hypothalamus, thus cannot exclude its potential contribution to EDS.
The lack of association found between EDS and levodopa or dopamine agonists may be due to the inaccuracies in recording the initiation of medication. Participants could start dopamine replacement therapy, at any point following their baseline visit, as part of their routine clinical care. Unfortunately, information regarding the medication dosage is not clearly
reported within the PPMI database, highlighting that the lack of correlation found between EDS development and dopamine replacement therapy is difficult to support.
Despite the uncertainty revolving around the causality, the presence of caudate impairment at the time of PD diagnosis can aid the identification of a sub-population at higher risk to develop EDS. This sub-population of PD patients might be included in clinical trials specifically designed to tackle their patterns of non-motor symptoms, which, although significantly impair quality of life, are poorly recognised and inadequately treated [5] .
Clinical experience has revealed that many non-motor symptoms, including dysautonomia and cognitive deficits, do not respond to dopaminergic treatment, though EDS is exacerbated by dopamine agonists. It is, therefore, fundamental to distinguish symptoms with a potential non-dopaminergic basis in order to make the correct choice of treatment. Delving deeper into the aetiology and mechanisms underlying non-motor symptoms will open avenues for the development of novel, effective drugs.
Simuni et al. [45] also explored the correlates of EDS, as defined by the Epworth Sleepiness Scale, in a cohort of early stage, de novo PD patients, which instigated us to determine whether a different measure of EDS arrives to similar conclusions. Simuni and colleagues similarly discovered associations between EDS and UPDRS Part-I and -II, autonomic dysfunction and depression [33] . However, they were unable to find an association between EDS and caudate [ 123 I]FP-CIT uptake or cognitive performance, as well as no difference in EDS prevalence between PD subjects and healthy controls. This could cast some doubt on whether the reported findings in this paper and the Simuni paper have any relevance to PD in particular. Given the de novo nature of the PD patients and their short disease durations, it could be possible that the correlations found may not be specific to Parkinson's disease per se, but the general population suffering from EDS. In this direction, EDS in early PD may be driven by factors unrelated to PD-specific pathology. Therefore, caudate denervation in EDSpositive PD patients, specifically, may simply pose as an indicator of other neural systems participating in the initiation and maintenance of sleep and alertness, which are affected in those suffering from daytime sleepiness, regardless of whether they are diagnosed with PD or not. Having said this, however, EDS is more frequent in treated patients, suggesting that either the progression of the disease and/or treatment may be critical in the development of this symptom, highlighting that, although there may not be differences in the prevalence of EDS within early PD compared to healthy controls, PD pathophysiology may propel this
multifaceted phenomenon, thus its relationship with other non-motor symptoms and cognitive impairment.
Understanding the pathophysiology of NMS, including determining which systems are involved, will encourage the development of therapies that can tackle the multicentric nature of PD, hence alleviate debilitating symptoms, including EDS. Though we found an association between EDS and caudate denervation, the pathophysiological causality is debateable. Therefore, impairment of dopaminergic function within the caudate should be further investigated to confirm its role in regulating the sleep-wake cycle. 
EDS = Excessive daytime sleepiness
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